PRLR and breast cancer: Indeed, these agents failed to show any antitumorigenic effects in a landmark multicenter clinical trial performed in PRLR expressors breast cancer patients (Novartis, 2016) (USA, Belgium, Italy and Spain), despite effective blockage of the PRLR, resulting in the termination of the trial (57, 58).